Suchergebnisse - "Arthritis"

PubPharm (83)

1

Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis : A Pharmacokinetic Modeling Study

enthalten in: Open access rheumatology : research and reviews | 2021

von Morrison, A. | Stauffer, M. | Kaufman, A.

2

CADTH reimbursement recommendation : indication: rheumatoid arthritis : recommendation : reimburse with conditionsInfliximab SC (Remsima SC)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH reimbursement review

Version: 1.0.

3

Clinical and economic review report : Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritisInfliximab SC (Remsima)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2021

CADTH common drug review

Version: Final (with redactions).

4

Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study

in: Open Access Rheumatology: Research and Reviews | 2021

von Morrison A | Stauffer ME | Kaufman AS

5

Characteristics of patients with rheumatoid arthritis undergoing primary total joint replacement : A 14-year trend analysis (2004-2017)

enthalten in: Modern rheumatology | 2020

von Asai, S. | Takahashi, N. | Asai, N. | +8

6

Clinical review report : indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq) (AbbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 2020

CADTH common drug review

7

Pharmacoeconomic review report : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq) (AbbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 2020

CADTH common drug review

Version: final.

8

CADTH Canadian drug expert committee recommendation : indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq -- abbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, February 2020

CADTH common drug review

Version: 1.0.

9

Pharmacoeconomic review report : (Eli Lilly Canada Inc.)Baricitinib (Olumiant)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, September 2019

CADTH common drug review

Version: final.

10

Clinical review report : (Eli Lilly Canada Inc.)Baricitinib (Olumiant)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, September 2019

CADTH common drug review

Version: final (with redactions).

1
2
3
4
5
6
7
8
9
Nächster »
[9]